Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's disease patients taking multiple anti-parkinsonian medications.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
- ACP-103 is an effective treatment for Parkinson's Disease with psychosis
- ACP-103 does not cause worsening of motor function in Parkinson's Disease
|Study Start Date:||March 2004|
|Estimated Study Completion Date:||December 2005|
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial of four weeks of ACP-103 treatment of psychosis in Parkinson's disease, with four weeks follow-up.
A total of 60 patients meeting entrance criteria will be randomly assigned to receive placebo (30 patients) or active drug (30 patients). Subjects will take study drug daily starting on Day 1. Dose escalations can occur on Study Days 8 and 15 only, and patients will receive a stable daily dosage from Day 16 until Day 28. Single step dose reductions are allowed during that period for adverse events or intolerance.
Patients will be evaluated at screening/baseline and at Study Days 1, 8, 15, 28, and 57 by raters blinded to the treatment. The major response variable will be motoric tolerability. Secondary response variables will be efficacy against psychosis and safety.
Currently, there are no approved drugs for this indication in the United States. Psychotic symptoms in Parkinson's disease patients are almost always stable, often non-threatening, and rarely paranoid or violent in content. The trial includes the requirement that each patient enrolled has a reliable caretaker who will accompany the patient to each visit who can reliably report on the patient's daily level of function. These factors argue for the safe inclusion of a four-week period of placebo treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00087542
|United States, California|
|Fountain Valley, California, United States, 92708|
|Sunnyvale, California, United States, 94089|
|United States, Connecticut|
|Danbury, Connecticut, United States, 06810|
|United States, Florida|
|Pompano Beach, Florida, United States, 33060|
|Tampa, Florida, United States, 33606|
|United States, Georgia|
|Atlanta, Georgia, United States, 30329|
|United States, Kansas|
|Kansas City, Kansas, United States, 66160|
|United States, Maryland|
|Elkridge, Maryland, United States, 21075|
|United States, New York|
|Albany, New York, United States, 12205|
|United States, North Carolina|
|Asheville, North Carolina, United States, 28806|
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19107|
|United States, Rhode Island|
|Pawtucket, Rhode Island, United States, 02860|
|United States, Tennessee|
|Brentwood, Tennessee, United States, 37027|